SCHEMBL30765704

SCHEMBL30765704

COC(=O)Cn1c(SC)ncc(N)c1=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.43
SMN1; SMN2 Q16637 6/20 0.43
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 2/20 0.42
NPC1 O15118 3/20 0.37
HTT P42858 1/20 0.37
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36
RAB9A P51151 2/20 0.36
TP53 P04637 1/20 0.36
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
CCND2 P30279 1/20 0.36
CCND3 P30281 1/20 0.36
MAPT P10636 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765971 0.84 POLB (0.38) KDM4EALDH1A1TP53POLB
SCHEMBL30765599 0.75 CTRC (0.54) KDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL23461141 0.70 KDM4E (0.46) KDM4ESMN1; SMN2ALDH1A1NPC1JAK2
SCHEMBL27459972 0.69 KDM4E (0.53) KDM4ESMN1; SMN2ALDH1A1HSD17B10NPC1
SCHEMBL30765906 0.69 SMN1; SMN2 (0.45) KDM4ESMN1; SMN2ALDH1A1HSD17B10NPC1
SCHEMBL23460858 0.69 KDM4E (0.48) KDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL23474380 0.68 KDM4E (0.41) KDM4EALDH1A1JAK2JAK1JAK3
SCHEMBL5565965 0.68 POLB (0.38) KDM4ESMN1; SMN2ALDH1A1HSD17B10NPC1
SCHEMBL11046960 0.68 ALDH1A1 (0.54) SMN1; SMN2ALDH1A1TP53MAPTPOLB
SCHEMBL30765661 0.68 MEN1 (0.48) KDM4ESMN1; SMN2ALDH1A1HSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed